This Press Release updates numerical list in reference sectionTheralase® validates previous University of Manitoba research ...

Theralase validates previous University of Manitoba research by demonstrating that RuvidarTM is safe and effective in the ...

Request To Download Free Sample of This Strategic Report @ Highlighted with 35 tables and 45 figures, this 111-page report ?Europe Genital Herpes Treatment Market 2022-2032 by Virus Type (HSV-1, ...

Global genital herpes treatment market will reach $5,051.8 million by 2032, growing by 4.7% annually over 2022-2032, driven by the rising prevalence of sexually transmitted diseases, changing ...

Certain antiviral and mAb therapies were shown to lower mortality and hospitalization rates in those infected with SARS-CoV-2 Omicron variants.

The overall market of herpes simplex is expected to boost with the expected launch of emerging therapy, increased awareness, and extensive research in the forecast period (2025-2034). LAS ...

Pregnant former Married at First Sight bride Elizabeth 'Lizzie' Sobinoff has revealed her recent debilitating health ...

NanoViricides, Inc. (NYSE American:NNVC) (the “Company”) declared today that it is ready to fight the bird flu with its revolutionary broad-spectrum antiviral drug NV-387, a drug that the Bird Flu ...

Clinical-stage pharma stock Theralase Technologies (TSXV:TLT) announced a significant breakthrough in the treatment of Herpes ...

University of Manitoba independent research verifies that RuvidarTM is more effective than acyclovir in the inactivation of Herpes Simplex Viruses post infection. TORONTO, ON / ACCESS Newswire / Febru ...

Chitosan, a naturally occurring polysaccharide derived from chitin, has demonstrated significant potential as an antiviral ...

Detailed price information for Theralase Technologies Inc (TLT-X) from The Globe and Mail including charting and trades.